<DOC>
	<DOCNO>NCT00996073</DOCNO>
	<brief_summary>The purpose study evaluate safety preliminary efficacy NeoFuse subject diagnosis degenerative disc disease ( DDD ) 1 2 adjacent vertebral level L1 S1 . All subject study undergo interbody fusion via Transforaminal Lumbar Interbody Fusion ( TLIF ) Posterior Lumbar Interbody Fusion ( PLIF ) procedures Food Drug Administration ( FDA ) approved/cleared supplemental posterior instrumentation .</brief_summary>
	<brief_title>Safety Preliminary Efficacy Study NeoFuse Subjects Requiring Lumbar Interbody Fusion</brief_title>
	<detailed_description>This prospective , multicenter , randomize , open-label control Phase 2 study design evaluate safety preliminary efficacy adult , allogeneic mesenchymal precursor cell ( MPCs ) combine MasterGraft Matrix compare use autologous iliac crest bone graft lumbar interbody fusion site subject require 1 2 level interbody fusion procedure instrumentation . All subject study undergo 1 2-level ( 2 3 vertebra ) interbody fusion supplemental posterior instrumentation . After screen surgical visit , subject evaluate clinically radiographically within 3 day 30 day surgery , 3 , 6 , 9 , 12 , 24 , 36 month surgery . Subjects evaluate time point safety .</detailed_description>
	<mesh_term>Spondylolisthesis</mesh_term>
	<mesh_term>Spinal Stenosis</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>1 . Male female least 18 year age , old 70 . 2 . Have ability understand requirement study , provide write informed consent , comply study protocol . 3 . Have ability understand provide write authorization use disclosure personal health information ( PHI ) [ per Health Insurance Portability Accountability Act ( HIPAA ) privacy rule US ] . 4 . Have document symptomatic diagnosis DDD L1S1 without stenosis without include Grade II degenerative spondylolisthesis . 5 . Have clinical symptom neurogenic claudication . 6 . Have fail 6 month nonoperative low back pain management . 7 . Are candidate posterior lumbar interbody fusion combination posterior pedicle screw stabilization require surgery 1 2 adjacent vertebral level L1 S1 . 8 . Have stable screen electrocardiogram ( ECG ) , determine investigator would preclude surgery . 1 . Female subject pregnant nursing , woman plan become pregnant first year ( 12 month ) follow surgery . Male subject partner childbearing potential must agree use adequate contraception ( barrier method abstinence ) time surgery period least 1 year surgery . 2 . Have current prior history within last 3 year neoplasm ( exclude basal cell carcinoma ) and/or active neoplasm within last 24 month , prior screen . 3 . Have osteoporosis define DEXA T score â‰¤ 3.0 history fragility fracture significant bone disease contraindicate use spinal instrumentation . 4 . Have document medical history radiographic evidence metabolic bone disease condition would negatively impact bone heal process . 5 . Have positive screen human immunodeficiency virus ( HIV ) antibody . 6 . Have treatment investigational therapy device within 6 month study surgery and/or plan participate allogeneic stem cell/progenitor cell therapy trial 3year followup period . 7 . Have recipient prior stem cell/progenitor cell therapy spinal fusion surgery . 8 . Have body mass index ( BMI ) &gt; 35 . 9 . Have 20 % great antihuman leukocyte antigen ( HLA ) antibody titer and/or antibody specificity donor HLA antigen . 10 . Are transient treat last 6 month enrollment alcohol and/or drug abuse inpatient substance abuse program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Degenerative disc disease</keyword>
	<keyword>Spondylolisthesis</keyword>
	<keyword>Spinal stenosis</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Adult Stem Cells</keyword>
	<keyword>Spinal Fusion</keyword>
	<keyword>Lumbar Spinal Fusion</keyword>
	<keyword>TLIF</keyword>
	<keyword>PLIF</keyword>
	<keyword>Mesoblast</keyword>
</DOC>